Exceptional charges of Rs 1,268.8 crore, including a US antitrust settlement and Organon acquisition costs, weighed on profit, while India formulation sales grew 17.3 per cent. Sun Pharmaceutical Industries, India’s largest drugmaker, on Friday reported a 36 per cent year-on-year decline in consolidated net profit to ₹1,988.5 crore for the second quarter of 2026-27 (FY27), weighed down by exceptional charges. Revenues from operations rose 11.9 per cent to ₹16,198.7 crore.